Preclinical investigation of artesunate as a therapeutic agent for hepatocellular carcinoma via impairment of glucosylceramidase-mediated autophagic degradation

Artesunate (ART) has been indicated as a candidate drug for hepatocellular carcinoma (HCC). Glucosylceramidase (GBA) is required for autophagic degradation. Whether ART regulates autophagic flux by targeting GBA in HCC remains to be defined. Herein, our data demonstrated that the dramatic overexpres...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wenjia, Ma, Zhaochen, Yu, Lingxiang, MAO, Xia, Ma, Nan, Guo, Xiaodong, Yin, Xiaoli, Jiang, Funeng, Wang, Qian, Wang, Jigang, Fang, Mingliang, Lin, Na, Zhang, Yanqiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535011/
https://www.ncbi.nlm.nih.gov/pubmed/36123535
http://dx.doi.org/10.1038/s12276-022-00780-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535011/
https://www.ncbi.nlm.nih.gov/pubmed/36123535
http://dx.doi.org/10.1038/s12276-022-00780-6

Ejemplares similares